Global Information
회사소개 | 문의 | 위시리스트

중국의 프레가발린(Pregabalin) 시장

Investigation Report on Chinese Pregabalin Market, 2020-2024

리서치사 China Research and Intelligence
발행일 2020년 01월 상품 코드 297272
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,678,000 Unprintable PDF (Single User License)
US $ 3,300 ₩ 4,018,000 Printable & Editable PDF (Enterprisewide License)


중국의 프레가발린(Pregabalin) 시장 Investigation Report on Chinese Pregabalin Market, 2020-2024
발행일 : 2020년 01월 페이지 정보 : 영문 30 Pages

2003년에 파이저는 프레가발린(상품명 '리리카')을 미국에서 등록했습니다. 2004년 12월에 프레가발린(Pregabalin)은 당뇨병성 신경병증성 통증 및 대상포진 후 신경통 치료제로 FDA에 의해 승인되었습니다. 프레가발린의 총매출은 200억 달러 이상입니다. 리리카의 세계 총매출액은 약 41억 달러로, 전년대비 13% 증가했습니다. 2010년에 리리카는 중국에서 승인되었습니다.

중국의 프레가발린 시장에 대해 조사분석했으며, 주요 제조업체의 시장 점유율, 병원 시장에서의 판매가격, 주요 제조업체 개요, 특허 상황, 병원 시장에서의 시장 점유율(제형별) 등을 정리하여 전해드립니다.

제1장 프레가발린 관련 개념

  • 적응
  • 세계 시장의 판매 상황

제2장 중국의 프레가발린 시장 개요

  • 중국으로의 프로세스
  • 주요 제조업체
  • 특허 상황
  • 시장규모

제3장 중국의 프레가발린 매출액 분석

  • 총매출액
  • 매출액 : 지역별

제4장 중국 프레가발린 주요 제조업체의 시장 점유율 분석

제5장 중국의 프레가발린(제형별) 시장규모 분석

제6장 중국 병원 시장의 프레가발린 기준가격

제7장 중국 프레가발린 시장의 주요 제조업체

  • Pfizer Deutschland GmbH
  • Chongqing Succeway Pharmaceutical Co., Ltd.

제8장 중국의 프레가발린 시장 전망

  • 중국의 간질 발생률 동향
  • 제네릭 의약품 상황
  • 시장규모 예측
  • 경쟁 패턴 예측

도표

KSA 14.03.20

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Pregabalin is a new-generation drug for neuralgia treatment. In Jul. 2004, it was approved by the European Union to treat some epileptic seizures in adults. In Dec. 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabetic peripheral neuralgia and postherpetic neuralgia. In 2006, generalized anxiety disorder and social anxiety disorder became new indications of Pregabalin. In 2007, Pregabalin was approved by the FDA as the first drug to treat fibromyalgia syndrome. In 2012, Pregabalin was approved by the FDA to treat spinal cord injury (SCI)-related pains. In 2010, Lyrica was approved to enter China.

According to CRI, the sales value of Lyrica increased by more than 450 times from about CNY 200,000 in 2010 to over 90.74 million in 2018. Due to Lyrica's success, many domestic manufacturers applied for Pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd.'s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer. By sales value, in 2018, Pfizer's Lyrica had a market share of approximately 77.13%, and the rest market share was captured by the products of Chongqing Succeway Pharmaceutical Co., Ltd. It is estimated that Pfizer's Lyrica will continue to dominate the Chinese market from 2020 to 2024 but its market share will decline because of the price competition of China-made Pregabalin.

According to CRI,there is a continuous rise in the number of people suffering from indications for Pregabalin. For example, the number of epileptics in China has exceeded 10 million and increases by 500 thousand every year. Therefore, Pregabalin has a bright prospect in China.

Topics covered:

  • Development environment of Chinese Pregabalin market
  • Governmental approval of Pregabalin in China
  • Prices of Pregabalin in China
  • Major Pregabalin manufacturers in China
  • Factors influencing the development of Chinese Pregabalin market
  • Prospects of Chinese Pregabalin market

Table of Contents

1 Relevant Concepts of Pregabalin

  • 1.1 Indication
  • 1.2 Development Process of Pregabalin in China
  • 1.3 Governmental Approval of Pregabalin in China
  • 1.4 Sales Value over the World

2 Market Overview of Pregabalin in China, 2013-2018

  • 2.1 Investigation on Sales Value of Pregabalin in China
    • 2.1.1 Total Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Investigation on Sales Volume of Pregabalin in China
    • 2.2.1 Total Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Investigation on Market Size of Pregabalin by Dosage Form in China, 2013-2018

3 Investigation on Market Share of Major Pregabalin Manufacturers in China, 2013-2018

  • 3.1 Major Manufacturers of Pregabalin
    • 3.1.1 Investigation on Market Share by sale value
    • 3.1.2 Investigation on Market Share by sale volume
  • 3.2 Pfizer
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales Value and Volume of Pregabalin Produced by Pfizer in China
  • 3.3 Chongqing Succeway Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales Value and Volume of Pregabalin Produced by Pfizer in China

4 Sales Price of Pregabalin in China Market, 2019

  • 4.1 Referential Price of Pregabalin in China Hospital Market
    • 4.1.1 Average Price in China
    • 4.1.2 Sales Price of Pregabalin by Region
  • 4.2 Referential Price of Pregabalin in China by Manufacturers
    • 4.2.1 Pfizer (Lyrica)
    • 4.2.2 Chongqing Succeway Pharmaceutical Co., Ltd.(Lairuike)

5 Prospect of Pregabalin Market, 2020-2024

  • 5.1 Factors influencing Pregabalin Market
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Generic Drugs
  • 5.3 Forecast on Market Size of Pregabalin in China, 2020-2024
  • 5.4 Forecast on Competition Pattern of Pregabalin in China

List of Charts

  • Chart Important Events in Development Process of Pregabalin
  • Chart Governmental Approval of Pregabalin in China
  • Chart Patent Information About Pregabalin Registration
  • Chart Sales Value of Pregabalin over the World
  • Chart Sales Value of Pregabalin in China, 2013-2018
  • Chart Sales Value of Pregabalin in Different Regions of China, 2018
  • Chart Sales Volume of Pregabalin in China, 2013-2018
  • Chart Sales Volume of Pregabalin in Different Regions of China, 2018
  • Chart Dosage form of Pregabalin in China
  • Chart Market Share of Pregabalin in China by sale value, 2013-2018
  • Chart Market Share of Pregabalin in China by sale volume, 2013-2018
  • Chart Enterprise Profile of Pfizer Inc.
  • Chart Sales Value and Volume of Pregabalin Produced by Pfizer in China, 2013-2018
  • Chart 3.5 Enterprise Profile of Chongqing Succeway Pharmaceutical Co., Ltd.
  • Chart Average Price of Pregabalin in China Market, 2013-2018
  • Chart Sales Price of Pregabalin by Region in China, 2017
  • Chart Referential Prices of Pregabalin Produced by Pfizer GmbH Arneimittelwerk (GE) in China, 2019
  • Chart Referential Prices of Pregabalin Produced by Chongqing Succeway Pharmaceutical Co., Ltd. in China, 2019
  • Chart Pregabalin Products Under NMPA's Approval by the End of 2019
  • Chart Forecast on Sales Value of Pregabalin in China, 2020-2024
  • Chart Forecast on Sales Volume of Pregabalin in China, 2020-2024
Back to Top
전화 문의
F A Q